| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BLFS | Common Stock | Award | +11,264 | +38% | 40,643 | 08 Mar 2024 | Direct | F1 | ||
| transaction | BLFS | Common Stock | Sale | $103,436 | -6,135 | -15% | $16.86 | 34,508 | 12 Mar 2024 | Direct | F2 |
| transaction | BLFS | Common Stock | Sale | $86,105 | -5,065 | -15% | $17.00 | 29,443 | 13 Mar 2024 | Direct |
| Id | Content |
|---|---|
| F1 | The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the grant date. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.60 to $17.11, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |